Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034149 | 1.00 | HTR1A (0.35) | HTR1APHGDHKDM4EL3MBTL1MEN1 | |
| SCHEMBL1038151 | 1.00 | HTR1A (0.35) | HTR1APHGDHKDM4EL3MBTL1MEN1 | |
| SCHEMBL1038469 | 0.91 | CRHR1 (0.34) | KDM4EL3MBTL1MEN1LMNAHPGD | |
| SCHEMBL2886656 | 0.91 | CRHR1 (0.34) | KDM4EL3MBTL1MEN1LMNAHPGD | |
| SCHEMBL1038238 | 0.85 | ITGB1 (0.40) | MEN1KMT2AMAPT | |
| SCHEMBL1039011 | 0.85 | TAS1R3 (0.37) | KDM4EMEN1LMNAHPGDKMT2A | |
| SCHEMBL1037255 | 0.85 | TAS1R3 (0.37) | KDM4EMEN1LMNAHPGDKMT2A | |
| SCHEMBL1039036 | 0.85 | TAS1R3 (0.37) | KDM4EMEN1LMNAHPGDKMT2A | |
| SCHEMBL1033416 | 0.84 | GSTP1 (0.31) | — | |
| SCHEMBL1035772 | 0.83 | ALDH1A1 (0.37) | KDM4EL3MBTL1MEN1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814891-B1 | BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES | BASF SE (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-7687657-B2 | Process for preparing acylphosphanes and derivatives thereof | CIBA SPECIALITY CHEMICALS CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080004464-A1 | Process for Preparing Acylphosphanes and Derivatives Thereof | IGM GROUP B.V. (NL) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004464-A1 | Process for Preparing Acylphosphanes and Derivatives Thereof | ME2, ME3, MEP1A | HTR1A 3472/4885PHGDH 162/4885KDM4E 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.